Back to top

Image: Bigstock

Why Amedisys (AMED) Could Be an Impressive Growth Stock

Read MoreHide Full Article

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is Amedisys, Inc. (AMED - Free Report) . This firm, which is in the Medical - Outpatient and Home Healthcare industry, saw EPS growth of 42.6% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of 62%. Furthermore, the long-term growth rate is currently an impressive 18.8%, suggesting pretty good prospects for the long haul.

Amedisys, Inc. Price and Consensus

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 5%. Thanks to this rise in earnings estimates, AMED has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank stocks here.

So, if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider AMED. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for AMED as well.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Amedisys, Inc. (AMED) - free report >>

Published in